Page 377«..1020..376377378379..390400..»

GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives – Business Wire

Posted: July 3, 2022 at 1:53 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GV20 Therapeutics, a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapeutics, announced three key executive appointments to accelerate its growth and transition into a clinical-stage company. Pioneering cancer researcher and co-founder Shirley Liu, Ph.D. was named the Chief Executive Officer; former executive at Shape Pharmaceuticals and Tensha Therapeutics, Steven Landau, M.D., became the Chief Medical Officer; and Genentech veteran Ying Gong, Ph.D. was appointed Chief Business Officer.

Shirley Liu is an innovative and prolific computational cancer biologist. Having been on the faculty at the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health for almost 20 years, she has made significant contributions to the understanding of gene regulation and drug response in cancer. Dr. Liu and Ted Xiao, Ph.D., a former postdoctoral fellow at Dana-Farber Cancer Institute and Harvard Medical School, co-founded GV20 Therapeutics in 2016 with the goal of applying high-throughput genomics and computational approaches to the discovery and development of novel cancer drugs. The companys efforts have led to the identification of novel targets and drug candidates including its first candidate, XBH25, a novel NK checkpoint inhibitor targeting solid tumors. GV20 expects to file an IND for XBH25 in the second half of 2022.

We are excited to welcome Steve and Ying and their expertise to the GV20 team, said CEO Shirley Liu. Ying and Steve both bring a wealth of experience advancing innovative oncology pipelines and building high-performing teams. That Ying and Steve have chosen to help lead GV20 at this crucial inflection point speaks to the power of our drug discovery capabilities and the potential of our pipeline. With their leadership, we are excited to advance XBH25 toward the clinic, and to discover more promising candidates at speed and scale with our integrated STEAD genomics and AI platform. We are well-positioned to bring next-generation immunotherapies to cancer patients.

ABOUT SHIRLEY LIU, PH.D.

Shirley Liu, Ph.D., co-founded GV20 Therapeutics in 2016 and joined the company full-time as the CEO in 2022. A highly cited cancer researcher, Dr. Liu was previously a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, and the co-director of the Center for Functional Cancer Epigenetics at Dana-Farber. With more than 250 peer-reviewed publications, her research has refined the understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers. She is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). Liu is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Dr. Liu received her Ph.D. in Biomedical Informatics and Ph.D. minor in Computer Science from Stanford.

ABOUT STEVEN LANDAU, M.D.

Steven Landau, M.D., has more than 25 years of experience developing products for the treatment of cancers and inflammatory diseases, including the FDA-approved monoclonal antibody Entyvio. He has previously served as Chief Medical Officer at oncology-focused companies including Shape Pharmaceuticals and Tensha Therapeutics. Dr. Landau has also supported product development at OraVax, LeukoSite, Millennium Pharmaceuticals, and Praecis Pharmaceuticals. Dr. Landau earned his M.D. from Case Western Reserve University, and completed his post-graduate training at the Beth Israel Hospital and the Brigham and Women's Hospital in Boston.

ABOUT YING GONG, PH.D.

Ying Gong, Ph.D., is an experienced strategist, drug developer and team leader. Most recently, she served as Project Team Leader for oncology at Genentech, where she led drug development programs and business development projects from late-stage research to clinical proof-of-concept. Dr. Gong also served as Senior Director of Portfolio Strategy and Planning, shaping Genentech's industry-leading R&D strategy. Prior to that, she held roles in medical affairs, market access, global product strategy, and market planning at Genentech and Roche, and worked on a broad range of projects including new indication launches of Perjeta and Avastin. She began her career as a management consultant at Bain & Company. Dr. Gong earned a Ph.D. in Biochemistry and Molecular Biophysics from the California Institute of Technology, and an M.A. in Molecular Genetics from Smith College.

ABOUT GV20 THERAPEUTICS

GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. The company closed a series B financing led by Coatue Management in October 2021. GV20 uses high-throughput functional genomics and artificial intelligence to identify novel cancer immunology drug targets and antibody therapeutics. The companys pipeline includes XBH25, a novel NK checkpoint inhibitor targeting solid tumors, which is currently progressing toward the clinic. GV20 references one of the most important acupoints for the human body, symbolizing the companys mission to find and exploit vulnerabilities in cancer biology.

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn and Twitter.

More:
GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives - Business Wire

Posted in Molecular Genetics | Comments Off on GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives – Business Wire

Research Assistant Professor / Scientific Officer, Department of Surgery job with THE UNIVERSITY OF HONG KONG | 299022 – Times Higher Education

Posted: July 3, 2022 at 1:53 am

Work type: Full-timeDepartment: Department of Surgery, School of Clinical Medicine (21700)Categories: Academic-related Staff

Applications are invited for appointment asResearch Assistant Professor (RAP)/Scientific Officer (SO) in the Department of Surgery, School of Clinical Medicine(Ref.:515452),to commence as soon as possible on a two-year fixed-term basis.

Applicants should possess a Ph.D. degree with proven experience in molecular genetics, next generation sequencing and cancer biology.They should have an excellent command of written and spoken English and Chinese (including Cantonese and Putonghua) and excellent communication skills. They should be outstanding and self-motivated researchers with a strong track record in molecular and cancer biology indicated by an excellent publication record. Post-doctoral experience in clinical studies and grant applications is essential.

The appointee will work independently and be involved in various projects related to breast cancer biology. He/She is expected to take up a leading role to oversee the team. Enquiries about the duties of the post should be directed to Professor Ava Kwong at avakwong@hku.hk.

A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits. At current rates, salaries tax does not exceed 15% of gross income. The appointment will attract a contract-end gratuity and University contribution to a retirement benefits scheme, totalling up to 15% of basic salary. For SO, housing benefits will also be provided as applicable.

The University only accepts online applications for the above post. Applicants should apply online and upload an up-to-date C.V.Review of applications will start on July 12, 2022 and continue untilJuly 31, 2022, or until the post is filled, whichever is earlier.

Read more:
Research Assistant Professor / Scientific Officer, Department of Surgery job with THE UNIVERSITY OF HONG KONG | 299022 - Times Higher Education

Posted in Molecular Genetics | Comments Off on Research Assistant Professor / Scientific Officer, Department of Surgery job with THE UNIVERSITY OF HONG KONG | 299022 – Times Higher Education

I’m Pregnant with My 5th Child & I’m Not Ashamed to Say Abortion is an Option – Yahoo Life

Posted: July 3, 2022 at 1:53 am

When I found out I was pregnant with my fifth child, my first words were, Oh my god, NO! I was alone in the bathroom while my husband was on a conference call, and all I could think of was how my life was ruined.

I texted my brother, asking him not to tell our mother yet because I was debating on whether or not to keep it. He texted back a wrap it up meme and I laughed, but inside, I was panicking.

More from SheKnows

I texted a friend, then multiple friends.

I waited impatiently by the door for my husbands call to end, and when he opened it, I practically threw the test at him. I cant quite recall exactly what happened except that there were lots of tears and he held me as I sobbed in his arms.

Click here to read the full article.

Im sorry I was selfish, he said.

You see, Ive been trying to get him to get a vasectomy for years. I was sick of hormonal birth control, sick of being the one in charge of birth control, sick of being the one tracking my ovulation, sick of the burden of me not getting pregnant being solely on my shoulders when he is an equal partner in the relationship. I had been on hormonal birth control for a decade prior to having children, and it wasnt until I was off it that I realized the hormones had wreaked havoc on my emotional state.

There was no way I was going back to that.

I know how babies are made, I replied.

And its true. I do.

Ive had 4 pregnancies and live births. Ive written countless articles about pregnancy, fertility, and womens health. I was a microbiology and molecular genetics major in college. I religiously track my ovulation and know its signs in my body, too.

I have always known I was pregnant either prior to a missed period or days after. Always.

This pregnancy was not a surprise. We both knew the risks of having unprotected sex particularly after I remembered I was ovulating. However, after more than five years of this same scare (look, you can know all the things and also be stupid and lazy) and having false alarms, we got complacent.

Story continues

So imagine my chagrin when about a week after having unprotected sex, my nipples were sore and Id been so exhausted that Id fallen asleep twice before 8:30 pm.

I took a pregnancy test two days before my expected period and it was negative. The sigh of immediate relief (albeit, accompanied with a slight twinge of disappointment) coursed through my entire body.

Of course, Id had thoughts of having a fifth child.

I love babies children not as much but I recognize that kids are the natural consequence of babies. My husband adores our children and considers them the best thing weve ever done (or will ever do). Were financially and emotionally able to have another child. And yes, the thought of having another fat, chubby baby to snuggle and nurse and hold was tempting.

But, I have also only recently reclaimed my life from 4 back-to-back pregnancies. Prior to this pregnancy, I have been pregnant for 3 years and nursed for over 9. I will be 44 years old in two months and already have four other kids aged 12, 10, 8, and 5.

My body is tired. I am tired.

So when I had a positive pregnancy test 4 days after my period was supposed to start, I was severely dismayed. More than that, I was terrified.

I mourned.

I would be restarting the clock on when I would have bodily autonomy without being tethered to a tiny human who needs so much. I realize its my job and function as a parent to provide that and also, my freedom will be severely restricted and I mourn that inevitability. They can both be true at the same time.

I will forever love and appreciate my husband for what he said to me after I finished crying. He said he was okay if I did not want to keep it that he would support me.

We discussed it at length and decided wed most likely choose to proceed with the pregnancy.

What if my husband hadnt been so supportive?

What if I didnt live in California, where it is legal up to 10 weeks pregnant to have a medical abortion (abortion via drugs) and 24 weeks for a surgical abortion?

What if I wasnt regularly having conversations about abortion with both my husband and our kids? (Yes, weve discussed the topic many times with my kids and in fact, when we told them about my pregnancy, I told them we might not keep it in order to normalize abortion.)

What if I still felt the effects of my Christian and sex-negative upbringing in regards to pregnancy and sex? What if I felt shame for even contemplating an abortion?

What if I could not afford to have this baby, did not have adequate healthcare, or did not have a vast network of people to help me?

I know that once this article publishes, I will receive hate emails and death threats because thats what happens every time I, a woman of color, publish an article that the establishment doesnt like. People will call me all sorts of vile names and threaten to report me to Child Protective Services (CPS).

But I also know that I have a lot of privilege in where I live, in being financially able to support this baby along with my other children, in having excellent healthcare, and in the fact that our livelihood is not dependent on me staying in the good graces of public opinion.

I tell you my story because I am confident that I am not the only person who is tired. I am not the only one who has children and has contemplated abortion despite being financially and emotionally capable of carrying a baby to term.

I tell you my story because Im sick of people dying.

Ultimately, the consequence of overturning Roe v. Wade is that people who did not need to die for want of a medical procedure, will.

According to the Guttmacher Institute, 930,000 abortions were performed in the U.S. in 2020, of which more than 1 in 3 were obtained in the 26 states that will, or are likely to, ban abortion. 13 of these states have trigger laws in place so that within days or hours of Roe v. Wade being overturned, bans were automatically enacted.

Evidence also shows the disproportionate and unequal impact abortion restrictions have on people who are already marginalized and oppressed, said Dr. Herminia Palacio, Guttmacher Institute President and CEO, in a recent statement. Including Black and Brown communities, other people of color, people with low incomes, young people, LGBTQ communities, immigrants and people with disabilities.

The overturning of Roe v. Wade isnt about states rights. Its about terrorizing our communities with the threat of maternal death, lost wages, disability due to complications in pregnancy, and shame.

And lets be real. The overturning of Roe v. Wade doesnt stop abortions for the privileged. Those who have access to money and networks will always have options with unwanted or life-threatening pregnancies; it is unacceptable that someone with fewer privileges and less access will not.

Ill be honest.

I did not want to tell people that I considered aborting this pregnancy, except I refuse to live in shame or hiding. I refuse to contribute to the further stigmatization of a perfectly reasonable option for a pregnant person, no matter what that reason may be.

If you are pregnant or can become pregnant, you deserve the option of easily ending a pregnancy. I know my story isnt terribly dramatic or exciting except thats exactly why its important. Abortion does not need to be dramatic or exciting. It just is. If my story can can be one tiny pebble joining all the other pebbles rippling across the world to make abortion legal, safe, and normal, it will have been worth all my discomfort.

Launch Gallery: Celebrities Who Opened Up About Having Abortions

Best of SheKnows

Sign up for SheKnows' Newsletter.For the latest news, follow us on Facebook, Twitter, and Instagram.

Excerpt from:
I'm Pregnant with My 5th Child & I'm Not Ashamed to Say Abortion is an Option - Yahoo Life

Posted in Molecular Genetics | Comments Off on I’m Pregnant with My 5th Child & I’m Not Ashamed to Say Abortion is an Option – Yahoo Life

Curbing Candida: The Cells That Keep Fungal Infections at Bay – Weizmann Wonder Wander – News, Features and Discoveries – Weizmann Institute of…

Posted: July 3, 2022 at 1:53 am

Of all the fungi that live in the human body, the most infamous is probably the yeast Candida. This distant cousin of bakers yeast is notorious for causing various types of thrush that can be a major nuisance, but it can also lead to an invasive infection that may, on occasion, prove fatal. In a study published today in Nature Immunology, a Weizmann Institute of Science research team headed by Prof. Jakub Abramson uncovered a previously unknown defense mechanism employed by the immune system in fighting Candida infections.

Candida is present at low levels in the bodies of most healthy people, forming part of the microbiome a diverse spectrum of microbes that reside peacefully in our gut and on our skin. Under normal circumstances, Candida is held in check by the immune system, but it can occasionally grow excessively, invading the lining of the mouth, the vagina, the skin or other parts of the body. In severe cases, it can spread to the bloodstream and from there to the kidneys. Such life-threating infections may occur when a persons immune system has been weakened, for example, by AIDS or by immunosuppressive drugs such as cancer chemotherapy or steroids. Antibiotics, which wipe out many of the beneficial bacteria within our microbiome, can also unleash local or invasive Candida eruptions by providing this yeast with an unfair advantage vis--vis other microorganisms. Thats why, for instance, women sometimes develop a vaginal yeast infection after taking antibiotics.

Until now, the immune cells that got most of the credit for defending the body against Candida were the small, round lymphocytes of the T cell type, called TH17. These cells were also the ones to take the blame when this defense failed.

In the new study, postdoctoral fellow Dr. Jan Dobe, working together with colleagues in Abramsons lab in Weizmanns Immunology and Regenerative Biology Department, discovered that a powerful commando unit of TH17 cells capable of fighting Candida cannot be generated without crucial early support from an entirely different contingent: a subset of rare lymphoid cells known as type-3 innate lymphoid cells, or ILC3, that express a gene called the autoimmune regulator, or Aire

The two groups of cells belong to the two different arms of the immune system, which, like foot patrols and specialized units, join forces against a common enemy. The Aire-ILC3s part of the more ancient, innate arm spring into action almost immediately upon encountering a threat in this case, a Candida infection. The TH17s belong to the immune systems more recent, adaptive arm, which takes several days or even weeks to respond, but which launches a much more targeted and potent attack than the innate one.

The scientists found that as soon as Candida starts infecting tissues, the Aire-ILC3s engulf the yeast whole, chop them up and display some of the yeast pieces on their surfaces. Thats how these bits are presented to the TH17s, a few of which are generally on call in the lymph nodes, ready for an infection alert. This kind of presentation instructs the specialized T cells to start dividing rapidly, soaring in number from a few lone commandos to several hundred or even thousands of Candida-specific fighters, capable of destroying the yeast at the sites of infection.

We have identified a previously unrecognized immune system weapon that is indispensable for orchestrating an effective response against the fungal infection, Abramson says.

Abramson became intrigued by Candida because it commonly leads to severe, chronic infections in people with a rare autoimmune syndrome caused by defects in the Aire gene. Abramsons lab had conducted extensive studies of this gene, helping to clarify its role in preventing autoimmune disorders. That research, as well as studies by other scientists, had shown that Aire-expressing cells in the thymus instruct developing T cells to refrain from attacking the bodys own tissues. When Aire is defective, T cells fail to receive proper instructions, consequently causing widespread autoimmunity that wreaks havoc in multiple body organs. But one puzzle remained: Why would Aire-deficient patients suffering from a devastating autoimmune syndrome also develop chronic Candida infections?

While trying to complete the Aire puzzle, Dobe and colleagues found that outside the thymus, Aire is also expressed in a small subset of ILC3s in the lymph nodes. The researchers then genetically engineered two groups of mice: One lacked Aire in the thymus, and the other group lacked it in the ILC3s in the lymph nodes. The first group developed autoimmunity but was able to successfully fight off Candida. In contrast, those in the second group, the ones lacking Aire in ILC3s, did not suffer from autoimmunity, but were unable to generate numerous Candida-specific TH17s. Consequently, they failed to effectively eliminate Candida infections. In other words, without Aire-expressing ILC3s, the specialized T cells needed for fighting Candida were not produced in sufficient numbers.

We found an entirely new role for Aire, one that it plays in the lymph nodes turning on a mechanism that increases the numbers of Candida-fighting T cells, Dobe explains.

These findings open up new directions of research that in the future may help develop new treatments for severe Candida, and possibly for other fungal infections. The newly discovered mechanism might, for example, help produce large numbers of Candida-fighting T cells to be used in cell therapy. And if scientists one day identify the signals by which Aire-ILC3s boost T cell proliferation, these signals themselves might provide the basis for new therapies.

Study participants also included Osher Ben-Nun, Amit Binyamin, Dr. Yael Goldfarb, Dr. Noam Kadouri, Yael Gruper, Tal Givony and Itay Zalayat of Weizmanns Immunology and Regenerative Biology Department; Dr. Liat Stoler-Barak and Prof. Ziv Shulman of the Systems Immunology Department; Katarna Kovov, Helena Bhmov and Evgeny Valter of Charles University, Prague; Bergithe E. Oftedal and Prof. Eystein S. Husebye of the University of Bergen, Norway; and Dr. Dominik Filipp of the Institute of Molecular Genetics of the Czech Academy of Sciences, Prague.

Link:
Curbing Candida: The Cells That Keep Fungal Infections at Bay - Weizmann Wonder Wander - News, Features and Discoveries - Weizmann Institute of...

Posted in Molecular Genetics | Comments Off on Curbing Candida: The Cells That Keep Fungal Infections at Bay – Weizmann Wonder Wander – News, Features and Discoveries – Weizmann Institute of…

More Fun Than Fun: Strife in the Harmonious World of Honey Bees, Part 2 – The Wire Science

Posted: July 3, 2022 at 1:53 am

A portion of the cape honey bee (Apis mellifera capensis) nest showing eggs laid not by the queen but by parasitic workers. These eggs can develop into future queens. Photo: Benjamin Oldroyd

Last month, we saw in part one of Strife in the Harmonious World of Honey Bees that although honey bees are renowned for their harmonious cooperation and efficient colonial life, there is nevertheless an underlying scope for conflict. Such conflict takes the form of disagreement over who should produce the males of the colony the queen or the workers. We saw that this conflict is all but suppressed by workers policing each other to prevent drone production and also by apparent self-restraint on the part of most workers.

We also saw that not all workers show adequate self-restraint and have some trick up their sleeves to evade policing by other workers. We saw that by a willingness to question the long-held assumption that workers produce much less than 1% of the drones, and by conducting a careful new study, Madeleine Beekman, Benjamin Oldroyd and their colleagues found that workers may produce as much as 4-6% of the drones.

The discovery of such cheating by worker bees was the culmination of a suspicion that had been building up for a quarter of a century.

In science, undertaking research with the explicit goal of calling into question, even deliberately hoping to overturn the work of previous researchers, is not an act of unkindness or meanness. The essence of science is that everything should be constantly questioned and examined for its continued validity. Science is a work in progress and needs to update itself continually. For this reason, we honour and venerate scientists but not their theories.

Anarchy in the hive

On October 27, 1994, a group of scientists from the School of Genetics and Human Variation, La Trobe University in Australia, published a sensational paper entitled Anarchy in the beehive. The group included Benjamin Oldroyd, whom we met in part 1 of this article, two other scientists, and the late Ross H. Crozier, well-known for his pioneering work on the evolutionary genetics of social behaviour. I vividly remember the excitement of reading this paper when it was first published. The manner in which they had discovered anarchic honey bees was as interesting as the phenomenon itself.

To detect whether workers cheat, i.e. whether they lay eggs even in the presence of a healthy queen, we need to determine whether a given egg was laid by the queen or the worker. While this can be done with fancy tools using molecular markers, where does one begin? Worker reproduction is expected to be quite rare, and only a very small percentage of the drone-producing eggs are expected to be laid by the workers.

Oldroyd and his colleagues devised a remarkably clever trick to solve this problem. At least for me, cleverness is significantly enhanced if the trick is simple and costs nothing when it is based on thinking out of the box rather than acquiring some new expensive technology. Such, indeed, was their trick.

Beekeepers keep honey bees in wooden boxes. The bees they keep (Apis mellifera in Europe, America, Africa and Australia; Apis cerana in Asia) normally nest in cavities in trees or rocks, and they build several parallel wax combs with cells on both sides. Beekeepers mimic this situation by providing several wooden frames in their boxes. Although the combs are at only one level in the natural colonies, beekeepers place one or more additional boxes on top of the basal box and let the workers move freely between the upper and lower boxes.

The queen, however, is confined to the lower box by the simple trick of placing a queen-excluder between the lower and upper boxes: its holes are large enough to let the workers through but not the much larger queen. The frames in the upper box are used to extract honey. Because the queen cannot visit the upper box, she lays all her eggs, male-destined and female-destined, in the frames in the lower box. And because workers normally do not lay eggs, there would be no eggs above the queen-excluder.

Thus, the honey extracted is not mixed up with the eggs. This is, of course, very convenient because the honey is pure vegetarian!

It occurred to Oldroyd and colleagues that this separation of eggs and honey can come in handy to discriminate between queen-laid eggs and worker-laid eggs. They argued that if any eggs are found above the queen-excluder, they are likely laid by workers. Brilliant!

But how many hives will you inspect to look for the improbable occurrence of worker-laid eggs above the queen-excluder? The answer is crowdsourcing! Like all good honeybee researchers, Oldroyd and his colleagues frequently interact with beekeepers. The association between honeybee researchers and beekeepers is reciprocal; both parties learn from each other. Beekeepers often have much experience-based wisdom, which is helpful to the researchers, and researchers occasionally make a few discoveries that may be useful to beekeepers.

So, Oldroyd and colleagues put out an advertisement seeking to know if any beekeepers have noticed eggs above the queen-excluders in their colonies.

Sure enough, they got a positive response. A beekeeper from Ipswich, Queensland, reported that his otherwise normal colony had more than 100 drone cells (drone cells are larger than those used for rearing workers or storing food) with brood in them, above the queen-excluder. This strongly indicated that workers may have laid the eggs that produced this brood.

Now, the researchers could focus on this single colony which was very promising for the possible discovery of anarchy in the hive. Using DNA-based markers, they genotyped the brood from above the queen-excluder, worker-destined brood from below the queen-excluder, and some adult workers.

The brood that shouldnt have been there

There were three possible hypotheses for the presence of a drone brood above the queen-excluder.

1. There may have been two queens in the colony, one trapped in the lower box and one in the upper box.

2. The workers may have carried the male-destined eggs laid by the queen in the lower box and placed them in the upper box.

3. Workers themselves may have laid the eggs that gave rise to the brood in the upper box.

Their results were clear. The colony had only one queen. Workers and not the queen sired all 49 pupae sampled from above the queen-excluder. Thus, hypotheses 1 and 2 were ruled out, and hypothesis 3 could be accepted. So they concluded that they had detected egg-laying by workers and dubbed this phenomenon anarchy in the hive. The justification for this catchy label is that, normally, worker ovaries are suppressed by the queen pheromone, and workers refrain from laying eggs and spend their time working for the welfare of the colony. But egg-laying by workers disrupts colony harmony and potentially creates anarchy.

Workers are known to develop their ovaries in the absence of the queen, but that is another matter easily understandable from the mechanistic (absence of queen pheromone) and evolutionary (no benefit of harmony) points of view.

Oldroyd and his colleagues had an even more exciting result. Honey bee queens mate with several males and simultaneously use sperm from different males so that the workers in a colony belong to many different patrilines. But they found that workers of a single patriline sired 48 of the 49 pupae located above the queen-excluder, a worker of another patriline sired one pupa, and all the remaining patrilines were unrepresented.

One patrilines monopoly of anarchic behaviour suggested that anarchic behaviour has a genetic basis and that some males had genes that would make their daughters anarchic. It is easy to see that natural selection would favour such selfish genes as long as they do not become too common.

Egg-laying by the anarchic workers is a different phenomenon, distinct from the small proportion of workers laid eggs that are quickly eaten by the police workers, which we saw in part 1 of this article. The eggs of anarchic workers are obviously not policed. Thus, anarchy is a complex phenotype requiring anarchic workers to evade the suppressing effect of the queen pheromone and develop their ovaries and lay eggs, which can go undetected by the police workers.

Breeding for anarchy

The next obvious step in unravelling the genetic basis of anarchy (or any trait) would be to see if the incidence of anarchy in colonies can be increased by selective breeding. To this end, Oldroyd and Katherine E. Osborne artificially inseminated some queens with sperm from drones sired by anarchic workers. As a control, they inseminated other queens with different proportions of sperm from drones sired by wild-type (normal) workers and sperm from drones sired by anarchic workers.

They found that when the queens were inseminated by sperm from drones of anarchic workers, the colonies headed by such queens showed a higher incidence of workers having developed ovaries and increased survival of worker-laid eggs. These results reinforce the possibility of a genetic basis for anarchic behaviour, involving increased tolerance to the queen pheromones inhibitory effects and increased ability to evade worker policing.

The colonies headed by queens inseminated with different mixtures of normal and anarchic sperm revealed a level of complexity that might have been missed were it not for these control colonies. The levels of anarchic behaviour seen in these colonies make it clear that the phenomenon of anarchy is the result of a complex interaction between the genotype of the queen, the genotypes of the different patrilines of workers, both anarchic and wild-type, and the external environment.

One never knows what a control experiment will reveal. It is a mistake to worry too much about whether a control experiment is really needed in view of our confidence that the main experiment is so clear-cut. Sometimes, it may be unclear what a control experiment will reveal and how it will help. That we do not know what the controlled experiment will reveal is itself an adequate justification for performing it.

In this case, it is not surprising, though in hindsight, that the expression of anarchy is so complicated. After all, the anarchic workers receive 50% of their genes from the queen and only 50% from their anarchic-gene-bearing fathers. Both sets of genes will influence their ability to resist the inhibitory effects of the queen pheromone and develop their ovaries.

Moreover, the survival of their eggs will depend on the policing efficiency of other workers in the colony belonging to different patrilines, based on their different abilities to sniff out their eggs.

Search for the anarchy gene

Now the search is on for the anarchy gene, which can confer these properties. An anarchy gene is the opposite of a social gene: the latter is expected to have the opposite effect, making the workers respond to the queen pheromone and refrain from developing their ovaries. If it is a gene that helps switch between developing and not developing worker ovaries, then we would have two birds in one shot we will have a gene that will prevent anarchy in one configuration and cause anarchy in another configuration.

In an unpublished preprint deposited in the increasingly popular database called bioRxiv, Oldroyd and his many colleagues have now reported a gene (technically a non-coding RNA) that seems a very promising candidate. It causes cell death in normal worker ovaries and prevents their development.

It is a striking irony that the study of strife in honey bee colonies, however rare, is finally helping us understand how strife is prevented under most conditions and how social organisation and cooperation evolve. It is often true in biology that we have to break the system or find a naturally occurring dysfunctional situation to understand the functional one by studying the abnormal, we understand the normal. This underscores the need to pay attention to exceptions and results that seem to contradict the prevailing paradigm.

A more serious threat to colony harmony

Dramatic as the story of anarchy in the hive is, the threat posed by anarchic workers to honey bee colonies is rather modest. Anarchic workers lay only male-destined eggs and therefore cannot produce future queens. Producing future queens remains the queens prerogative, so there is no danger that queens will lose all their fitness.

The fact that worker anatomy has been sufficiently modified to prevent them from mating is a powerful safeguard against cheating. Thus, the queen continues propagating her genes by maintaining a reasonable degree of harmony in the colony because workers cannot produce diploid female-destined eggs without mating. We might therefore say that anarchic workers do not pose an existential threat to the queen.

But nature forever springs surprises at us. The southernmost part of South Africa has a truly remarkable subspecies of honey bees, appropriately called Apis mellifera capensis. In the cape honey bee, as this is often called, workers can indeed pose an existential threat to their queens and to queens of other capensis colonies as well as to queens of the sister subspecies Apis mellifera scutellata in the neighbourhood.

This is because capensis workers can lay diploid eggs, which develop into females, either into workers or queens, depending on how the larvae are fed.1 Thus, capensis workers can produce new queens, usurping what is usually the exclusive prerogative of the queens in all other subspecies of honey bees.

The remarkable phenomenon of cape honey bee workers frequently developing their ovaries and laying male and female destined eggs was discovered by one George William Onions (1867-1941), a carpenter in South Africa with no specialised training but with beekeeping as a hobby. As is often the case, his discovery was met with much scepticism during his lifetime. But today, it is a well-established fact and the subject of great interest.

How do capensis workers manage to lay diploid eggs? Surely, they have not reversed their anatomical loss of the ability to mate. What they do is no less remarkable. I found it more extraordinary still that what they do was demonstrated by a relatively unknown Indian scientist, named Savitri Verma.

All diploid organisms with two sets of chromosomes must reduce the diploid number by half to produce haploid gametes to restore the diploid number when sperm meets eggs to make the next generation. The reduction of the chromosome number happens during the process of cell division, known as meiosis.

Meiosis consists of two consecutive cell divisions, the first reductional and the second mitotic, i.e. equational, resulting in four haploid cells. In contrast, mitosis is the process by which somatic cells divide without reducing the number of chromosomes.

The question of interest is whether reduction of chromosome number never happens in capensis bees or whether it happens, and then two haploid cells fuse at the end of meiosis to restore diploidy. The latter idea is not as outrageous as it sounds because, after all, it is the destiny of the haploid products of meiosis to fuse with other haploid cells to restore diploidy, except that they usually fuse with haploid gametes from another individual of the opposite sex.

In this case, the fusion would be, if that is how it happens, among the haploid cells of the same individual and thus a form of parthenogenesis. This form of parthenogenesis, in which the diploid female bee produces diploid female offspring without mating, is called thelytoky. It is distinct from arrhenotoky, the other (more usual) kind of parthenogenesis in which a diploid female bee produces haploid male offspring without mating. In arrhenotoky, the haploid products of meiosis directly develop into haploid adult males.

Savitri Verma worked with Friedrich Ruttner, the well-known honey bee biologist at the University of Frankfurt in Germany. They examined what is often called the dance of the chromosomes under the microscope to distinguish between the two hypotheses: no reduction in chromosome number or reduction followed by restoration of diploidy by cell fusion. She demonstrated clear evidence of reduction followed by fusion to restore diploidy.

Here, I want to pay tribute to Savitri Verma for her pioneering work of great significance, especially because she is all but unknown to the scientific community, even in India. As irony would have it, the paper that made her immortal is sometimes cited in high profile journals not correctly as Verma, S. and F. Ruttner (1983) but incorrectly as Verma, L.R. and F. Ruttner (1983).

Verma L.R. is her better-known husband and also a honey bee biologist!

Scientists are pretty lax about ensuring the accuracy of their citations, so they frequently copy the required citations second-hand from any paper that has already made the citation, often without accessing or reading the original paper being cited. This can lead to the perpetuation of inadvertent citation errors, especially if the wrong citation appears in a prominent paper likely to be used as the source for copying citations.

Reference lists in scientific papers are like silent genes that are free to mutate, unchecked by natural selection in the form of proofreading. It would make an interesting student project to determine the frequency of citation errors in scientific papers.

Savitri Verma obtained her PhD from the University of Frankfurt, Germany, and returned to India to pursue a distinguished teaching and research career in India in the fields of cytogenetics, molecular biology and human genetics. She retired in 2009 as senior professor and head at the University of Shimla in Himachal Pradesh.

The phenomenon of capensis workers laying female-destined eggs discovered by George William Onions a century ago and whose cytological mechanism was elucidated by Savitri Verma and Friedrich Ruttner some 40 years ago is now at the forefront of research in honey bee genetics and evolution, with considerable ramifications for beekeeping too.

The cape honey bee (Apis mellifera capensis) is turning out to be even more remarkable than was originally believed. Large numbers of capensis workers develop their ovaries and lay diploid eggs. These eggs are not policed, apparently because they are chemically indistinguishable from queen-laid eggs.

Interestingly, capensis workers do not police their sisters thelytokous eggs even though they police worker-laid eggs introduced experimentally from the subspecies scutellata. Thus, in addition to being queen-like, capensis workers also lay eggs that are also queen-like.

Although capensis queens can mate and produce daughters sexually, utilising sperm from males, virgin queens can lay both arrhenotokous haploid male-producing eggs and thelytokous diploid female-producing eggs suggesting that they can control which kind of meiosis their eggs go through even after they are laid.

Recently, a gene that controls the switch between thelytoky and arrhenotoky has been identified. The social disharmony-causing thelytoky in cape bees may help us understand the molecular basis of meiosis. Such are the ways of biology!

Not only do capensis workers lay eggs that can be reared as queens, they seem to have a competitive edge over their queens. In one study, 23 out of 39 queens produced were sired by workers. If queens are experimentally removed, capensis workers prefer to rear new queens from worker-laid thelytokous eggs ignoring queen-laid eggs that the experimenter may provide.

But queens have a different trick up their sleeve. They can pass on 100% of the genes to future queens by producing new queens, thelytokously avoid male genes altogether. Each one for herself such a far cry from the harmonious cooperation and altruism that we expect from honey bees.

The cape bees ability to create strife is not restricted to competition between workers and her queen within the colony. Much greater fitness payoffs await workers who enter and parasitise colonies of other honey bee subspecies. Capensis queens produce more pheromones to keep their workers in check.

So, a capensis worker entering the colony of another subspecies encounters less queen pheromone than she is used to. She, therefore, develops her ovaries even faster and lays potentially queen-destined eggs rapidly. Worse, she may kill the queen and put the host workers to work to rear her daughter queens.

Beekeeping practices further exacerbate the capensis workers parasitic tendencies. Capensis bees can enter a commercial beehive and start a little nursery of their own daughters in the upper box to which the host queen has no access. Sometime later, the mother parasite and her daughters can go down and attack the host queen. They will have little interest in the welfare of the host colony. Once they utilise the resources of the host colony, they can quit and enter another healthy colony.

A little tweaking of the meiotic cell division has allowed the cape honey bee to utilise all the features meant to ensure harmonious social life into a nefarious antisocial lifestyle. Not surprisingly, this has dire consequences for the beekeeping industry. How can one practice beekeeping if your colonies parasitise and destroy each other in the game of one-upmanship? Beekeepers rely on harmony and cooperation in the hive to make their living.

Dysfunction in the hive?

Two well-known honey bee researchers, Robin Moritz from the University of Halle in Germany and Robin Crewe from the University of Pretoria in South Africa, have now taken a holistic view of the various features of honey bees that make them seem less than perfect harmonious societies. In a recent book ruthlessly entitled The Dark Side of the Hive (2018), Mortiz and Crew tear apart the long-held perfectionist view of honey bee societies and conclude:

The honey bee colony is thus far from being a harmonious, cooperative whole. It is full of individual mistakes, obvious maladaptations, and evolutionary dead ends. Conflict, cheating, worker inefficiency, and curious reproduction strategies all occur.

The Dark Side of the Hive is one of the most shocking science books I have read. Brimming with out-of-the-box thinking and a large dose of heresy, Moritz and Crewe tear into the prevailing complacent and admiring view of honey bees and look at the dark side of every aspect of honey-bee biology.

To take just one example, they list all the problems associated with the difficult diet of the honey bees. Their vegan diet, with its exclusive dependence on nectar and pollen, presents myriad problems. The bees have to transport large quantities of liquid. Since a bee can transport only about 25 mg of nectar at a time, they need some 400,000 foraging trips to gather the nectar to make one kilogram of honey.

To give us a feel for what that means, we are told that this is equivalent to a return flight to the Moon and back! So, how do the bees solve this problem?

The queen produces hundreds of thousands of workers to share the burden. But this means a massive investment in the non-reproductive worker force to produce just a few queens and drones, not to mention the difficulties of housing and managing the large population of workers.

Nectar is a dilute sugar solution and will quickly go bad and ferment, so they expend a considerable effort to evaporate the water and concentrate it into a thick syrup. But that poses its own problems as viscous honey can stick to the bees bodies, block their trachea and kill them by asphyxiation. So they spend much time and energy constantly grooming themselves.

The story with pollen is not much different. Pollen is fine dust that the bees must harvest and bring home in large quantities while constantly cleaning themselves to prevent their trachea being blocked. Digesting pollen presents its own problems. The thick indigestible coating of the pollen must be excreted in large amounts and going out of the hive to do so presents another challenge, especially in the winter.

The pollen diet presents an even more significant challenge to the larvae, who dont defecate until they become pupae. Besides, to preserve pollen and maintain its nutritional quality, the bees process it and make bee bread.

The ancestors of honey bees mass provision their larvae, i.e. they add all the food required for the development of the larvae into the cells before laying an egg in it. Honey bees, however, have evolved progressive provisioning: they frequently feed the larvae, altering the diet and adding secretions as appropriate. This is a huge undertaking.

In this vein, Moritz and Crewe find fault with every aspect of honey bee biology. I found their approach to bee biology absolutely fascinating, although it appeared perverse at first, I must confess. I knew most of the facts they present but had not thought about them in this light.

Robin Moritz told me in an email that he and Crewe were inspired to write The Dark Side of the Hive because of their conviction that Nobody is perfect (and bees definitely not) but then there is no need to be perfect in order to become evolutionarily successful.

Moritz and Crewe dont just indict the honey bees. With powerful arguments, they indict the research strategies and methodologies of scientists involved in honey bee research.

The picture of harmony and success is compelling, sometimes perhaps so compelling that it might easily preclude asking critical questions about such obvious efficiency, they write. And The perfection that is perceived to exist in their social organisation is a function of a particular experimental focus on the colony as a whole rather than exploring the idiosyncrasies of its individual members, they argue.

Finally, they tell us that they instead, explore the situations in which individual interests are pursued often at the expense of the colony, and show that the solutions that have evolved are often less than optimal.

One of their main criticisms concerns a central debate in evolutionary biology. Does natural selection act to make the best colonies fit enough to compete with other colonies, or does it make the best individuals fit enough to compete with other individuals, even within the same colony? The answer must be both. But the interesting unknown is how the trade-off between the two levels of selection plays out in different situations. This should be the topic of much future research.

The Dark Side of the Hive has had a profound effect on me. It has shown me how I was blind to the possible alternate interpretations of well-known facts. It has made me worried about my interpretation of other fields of knowledge. I recommend that not only students of honey bees and other social insects but also all biologists should read The Dark Side of the Hive by Moritz and Crewe alongside other wonderful books such as Biology of the Honey Bee by Mark L. Winston, The Wisdom of the Hive and Honeybee Democracy by Thomas D. Seeley and The Spirit of the Hive and Art of the Bee by Robert E. Page, which focus primarily on the bright side of the hive.

The true essence of what we have learnt about honey bees in this two-part article is that honey bees have an uncanny ability to manage conflict, display a semblance of normalcy and become evolutionarily successful despite great scope for conflict and inherent dysfunctional tendencies making them even more impressive and more worthy of the epithet a prime favorite of the gods, as William Morton Wheeler lyrically described them almost a century ago. And surely there is something for us humans to learn from the bees here.

Raghavendra Gadagkar is a Department of Science and Technology (DST) Year of Science Chair Professor at the Centre for Ecological Sciences at the Indian Institute of Science, Bengaluru.

The rest is here:
More Fun Than Fun: Strife in the Harmonious World of Honey Bees, Part 2 - The Wire Science

Posted in Molecular Genetics | Comments Off on More Fun Than Fun: Strife in the Harmonious World of Honey Bees, Part 2 – The Wire Science

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors -…

Posted: July 3, 2022 at 1:53 am

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Companys Scientific Board of Advisors. In addition, Dr. Jay Lalezari has agreed to serve as an outside Scientific Advisor to the Company.

Dr. Paul Edison is a Senior Clinical Lecturer in Neuroscience in the Department of Brain Sciences at Imperial College London and an honorary Professor at Cardiff University. He is also the Editor-in-Chief of the journal Brain Connectivity. After his clinical training (MD), Dr. Edison received his MPhil and Ph.D. from Imperial College London, and then completed his higher training in London Deanery and obtained his CCT from the Postgraduate Medical Education and Training Board. He then became a Fellow of the Royal College of Physicians, Ireland, and Fellow of the Royal College of Physicians, UK. He has published in such highly regarded journals as Brain, Annals of Neurology, and Neurology, and has received grants from the Medical Research Council, NIHR/HEFCE, Alzheimers Society, Alzheimers Research UK, Alzheimers Drug Discovery Foundation US, and other funders. He collaborates closely with Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences, and Astra Zeneca. He has also received several best paper awards internationally and published in leading scientific journals. His work now focuses on neuroinflammation and the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease, and relating these with genetic information. He is also evaluating the methods of modulating inflammation and amyloid in Alzheimers disease, and the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and pre-clinical studies.

Dr. Kabir Mody is the Medical Director at IMV, Inc. and a board-certified medical oncologist. He brings a wealth of experience and knowledge in oncology and immuno-oncology accumulated while working at Mayo Clinic as an academic oncologist focused on GI oncology, particularly cancers of the liver and the pancreas. Dr. Mody received his MD from St. George's University School of Medicine, and completed his residency at St. Lukes-Roosevelt Hospital in New York City, and a fellowship at Dartmouth Hitchcock Medical Center in New Hampshire. He has co-authored numerous papers and book chapters, including many on the biology and novel treatment strategies of liver and pancreas malignancies, and has been actively involved in leading both clinical and lab-based research on cancers of the liver and pancreas.

Dr. Otto Yang is a Professor of Medicine, Infectious Diseases, Microbiology, Immunology & Molecular Genetics at UCLA and has a background in clinical infectious diseases. His laboratory specializes in T cell immunology in HIV infection, relevant to developing immune therapies and vaccines for HIV and potentially other diseases, including cancer and other viral infections. He received his MD degree from Brown University, with subsequent residency training at NYU-Bellevue Hospital and subspecialty/postdoctoral training at Harvard-Massachusetts General Hospital. He then pursued a fellowship at Massachusetts General Hospital, where he developed a research program studying the role of CD8+ T lymphocytes (CTL, which are killer T cells that can destroy cells infected with viruses or which are malignant) in HIV-1 pathogenesis. A more recent research interest has been the role of CTL in the development of rejection in organ transplant patients. Dr. Yang has begun working with the new composite tissue transplantation program at UCLA, which will perform hand and face transplants, studying the role of this arm of immunity in causing tissue rejection. Dr. Yang is a frequent lecturer, has received numerous research grants and funding for his work and published over 180 peer-reviewed articles, and holds numerous patents in HIV and Immunology.

Dr. Jacob (Jay) Lalezari has agreed to serve as an outside Scientific Advisor to CytoDyn without compensation. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1997. He received his MD degree from the University of Pennsylvania and his MA from the University of Virginia. He also received a BA from the University of Rochester. He received his board certification from the American Board of Internal Medicine. He briefly served as interim Chief Medical Officer of CytoDyn during 2020, as well as Chief Medical Officer of Virion Therapeutics. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, Influenza, RSV, and COVID-19, including clinical trials conducted by the Company. He has published extensively and is a well-regarded international speaker and patient advocate.

About CytoDyn

CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.

Forward-Looking StatementsThis press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the regulatory determinations of leronlimabs safety and effectiveness to treat the diseases and conditions for which we are studying the product by the U.S. Food and Drug Administration (FDA) and various drug regulatory agencies in other countries; (ii) the Companys ability to raise additional capital to fund its operations; (iii) the Companys ability to meet its debt obligations; (iv) the Companys ability to recruit a permanent CEO and retain other key employees; (v) the Companys ability to enter into partnership or licensing arrangements with third-parties; (vi) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion; (vii) the timely and sufficient development, through internal resources or third-party consultants, of analyses of the data generated from the Companys clinical trials required by the FDA or other regulatory agencies in connection with applications for approval of the Companys drug product; (viii) the Companys ability to achieve approval of a marketable product; (ix) the design, implementation and conduct of the Companys clinical trials; (x) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results; (xi) the market for, and marketability of, any product that is approved; (xii) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products; (xiii) regulatory initiatives, compliance with governmental regulations and the regulatory approval process; (xiv) legal proceedings, investigations or inquiries affecting the Company or its products; (xv) general economic and business conditions; (xvi) changes in foreign, political, and social conditions; (xvii) stockholder actions or proposals with regard to the Company, its management, or its board of directors; and (xviii) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, as well as risk factors and cautionary statements included in subsequent Form 10-Qs and Form 8-Ks, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSInvestors: Cristina De LeonOffice: 360.980.8524[emailprotected]

Media:Joe Germani / Miller WinstonLongacre Square Partners[emailprotected] / [emailprotected]

Here is the original post:
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors -...

Posted in Molecular Genetics | Comments Off on CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors -…

Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation…

Posted: July 3, 2022 at 1:52 am

DetailsCategory: DNA RNA and CellsPublished on Saturday, 02 July 2022 13:59Hits: 289

MORRISVILLE, NC, USA I June 30, 2022 I Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota. The aim of this collaboration is to build a novel induced pluripotent stem cells (iPSC) platform that will accelerate Inceptor Bio's best-in-class next-generation cell therapies platforms. Under the terms of the agreement, Inceptor Bio will receive an exclusive license to the technology developed under this collaboration.

Inceptor Bio plans to advance multiple cell therapy products into clinical studies incorporating the iPSC platform into its proprietary K62 platform for CAR-M therapy, which increases the phagocytic capabilities of macrophages and supports an M1 anti-tumor phenotype, as well as its novel co-stimulatory domain, M83, for CAR-NK therapies.

"iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies. We are excited to work with Dr. Beau Webber at University of Minnesota and his team to develop this unique platform," said Mike Nicholson, Ph.D., President and Chief Operating Officer at Inceptor Bio.

"The team at University of Minnesota is confident that Inceptor Bio is the right partner for building a differentiated iPSC platform to advance novel cell therapies," saidBeau Webber, Ph.D., Assistant Professor in the Department of Pediatrics, Division of Hematology and Oncology. "We are deeply encouraged by Inceptor Bio's progress in the cell therapy arena, and we look forward to being part of future developments to help cure difficult-to-treat cancers."

"This partnership is an important step in continuing to execute on our strategy of advancing cell therapies to bring a more positive prognosis and quality of life to patients with difficult-to-treat cancers," said Abe Maingi, Vice President, Business Development at Inceptor Bio. "We are thrilled to be able to develop and deliver on the promise of iPSC-derived cell therapies."

About Inceptor Bio

Inceptor Bio is a biotechnology company developing multiple next-generation cell therapy platforms to deliver cures for underserved and difficult-to-treat cancers. Inceptor Bio is building platforms in CAR-T, CAR-M, and CAR-NK. Inceptor Bio is headquartered in Morrisville, North Carolina. More information is available at http://www.inceptor.bio.

SOURCE: Inceptor Bio

Read the original post:
Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation...

Posted in North Carolina Stem Cells | Comments Off on Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation…

W-S organization working on regenerative therapies for 40 organs, tissues – WRAL TechWire

Posted: July 3, 2022 at 1:52 am

WINSTON-SALEM Human organ transplants became possible in 1954 when a kidney became the first organ to be transplanted successfully, eventually earning Boston physician Joseph Murray the Nobel Prize.

Today, its also possible to receive a transplanted heart, lungs, liver, pancreas or intestines, as well as tissues including skin, bone, corneas, tendons, ligaments and blood vessels.

A record-high number of organ transplants 41,354 were performed in the United States in 2021, according to the United Network for Organ Sharing, a nonprofit organization that supports the nations transplant system. It was the first year that organ transplants exceeded 40,000.

Despite the progress made in organ transplantation over the last seven decades, the demand for organs still greatly out-strips the supply, a trend unlikely to reverse.

Even though organ transplants are out there, the challenge is that more patients are dying every day from organ failure, and the numbers are fairly shocking actually, saidAnthony Atala, M.D., an internationally acclaimed urologist, researcher and professor at the Wake Forest University School of Medicine. So thats where regenerative medicine comes in.

Atala is director of theWake Forest Institute for Regenerative Medicine(WFIRM), a translational research organization devoted to bringing new treatments and cures to patients with diseased or damaged organs or tissues. He highlighted WFIRMs activities and impact as the keynote speaker at Triad BioNight, a dinner and awards event held June 23 at High Point University and sponsored by the North Carolina Biotechnology Center.

Piedmont Triad bioscience leaders honored with awards at Triad BioNight

Atalas appearance at the event reinforced the mutual admiration between him and NCBiotech that dates back to his arrival at the Triad university in 2004. The Biotech Center has awarded numerous grants to various members of his lab over the years, and Atala has also served on the NCBiotech board of directors.

NCBiotech has provided $352,476.32 in grants to Wake Forest University for regenerative medicine-associated research during Atalas 18 years at the university. The Center has awarded an additional $75,883.62 in meeting, event, and educational grants for regenerative medicine-related programming during the same time, including an active $10,000 award for an upcoming meeting.

It is clear to see how over time, this regional effort has global impact, said Nancy Johnston, executive director of NCBiotechs Piedmont Triad Office. New initiatives underway indicate there is power in partnerships and place; value in investing in innovation; and the top talent it takes in this emerging field of regenerative medicine.

Regenerative Medicine The Driving Force for Dr. Anthony Atala

Atala told the crowd of nearly 400 attendees that WFIRMs scientists, technicians and physicians are working on regenerative medicine therapies for about 40 different organs and tissues, building on 15 applications that have been used in patients to date.

We have an amazing team over 450 people all working together to bring these technologies from the bench to the bedside, Atala said.

WFIRM is based in a five-story building spanning about 200,000 square feet in Winston-SalemsInnovation Quarter, a downtown district devoted to research and technology enterprises.

We do everything here, from the idea, to the concepts, to the proof of principle at the benchtop, to the preclinical work, all the way to the manufacturing of the product in an FDA-compliant facility right in this building, Atala said.

WFIRM scientists and physicians made history in 1999 when they were the first in the world to implant laboratory-grown organs into humans.Seven children with spina bifida and severely malfunctioning bladders received grafts of rudimentary bladders engineered in Winston-Salem.

Today WFIRMs multidisciplinary work uses cells, bioreactors, tissue engineering, biomaterials, 3D bioprinting, small molecules, gene editing, body-on-a-chip technologies and personalized medicine approaches to innovate new therapies and diagnostics.

NC bio startup raises $15.5M to advance 4D printing of human organs

Cell therapy the use of harvested and cultured cells to restore tissues and organs is a major thrust of WFIRMs work. The technology offers a great advantage over donated organs and tissues because it typically uses a patients own cells, thereby avoiding rejection by the bodys immune system.

Working with cell media in the Atala lab.

Work is under way at WFIRM to use skeletal muscle cells to restore lost muscle function in patients with urinary incontinence and in patients undergoing rotator cuff repair surgery.

In both cases, skeletal muscle cells are collected from a tissue sample smaller than a postage stamp, are multiplied in the lab, and are then injected into the body to build muscle.

Researchers are also working with a type of stem cell taken from the amniotic fluid or placenta after a woman gives birth. WFIRM scientists were the first in the world to identify and characterize stem cells derived from amniotic fluid in 2007 and since then have developed techniques for isolating and expanding the cells.

These cells are very powerful, Atala said. They can grow into all three different major categories of cells that lead to every cell in your body.

WFIRM is investigating the use of these cells as potential therapies for patients with chronic kidney disease.

W-S biotech firm Plakous Therapeutics wins NC BIONEER Venture Challenge

Cell therapy often involves the use of biomaterials that can be shaped into scaffolds that mimic the shape of a tissue or organ. Different materials can be mixed and matched for various tissue reconstruction.

One application is for helping patients with a damaged urethra, the duct that drains urine from the bladder. A tubular-shaped scaffold is coated inside and outside with muscle cells that are taken from the patient and multiplied, then the scaffold is placed in an oven-like device to encourage cell growth.

Its very much like baking a layer cake, Atala said, eliciting chuckles from the audience. Once its completed you actually put it back into the patient.

The implanted scaffold biodegrades in the body after six months, but the cells remain viable indefinitely.You end up with your very own cells, your very own bridge and your very own organ, Atala said.

WFIRM researchers have successfully engineered replacement tissues and organs of all four shapes found in the body flat structures, tubular tissues, hollow organs and solid organs.

Federal grant will boost training opportunities for students in regenerative medicine

WFIRM is also a pioneer in 3D bioprinting, the use of printer-like devices to deposit layers of living cells in three-dimensional patterns. The invention, inspired by desktop ink jet printers, brings precision and automation to the construction of tissues and organs.

Last year two teams of scientists from WFIRM used 3D bioprinting to win first and second place in NASAsVascular Tissue Challenge, a national competition to accelerate tissue engineering innovations that might benefit people on Earth today and space explorers in the future.

The WFIRM teams created lab-grown human liver tissues that were strong enough to survive and function in ways similar to those inside the body. They each used a varied 3D printing technique to construct a cube-shaped tissue about one centimeter thick and capable of functioning for 30 days in the lab.

That was a major challenge, Atala said, because anything over the size of a pinhead will not get nutrition.

Tissues in the body rely on blood vessels to supply cells with nutrients and oxygen and remove metabolic waste. Recreating this process in engineered tissue is difficult, so NASA asked teams to develop and test strategies for making tissues with functional artificial blood vessels.

Wake Forest researchers win NASA challenge to develop lab-grown human vascular tissue

The winning teams used 3D printing to create gel-like molds with a network of channels designed to maintain sufficient oxygen and nutrient levels to keep the constructed tissues alive.

The two teams collectively won $400,000 while no other team in the national competition qualified for third place.

Another WFIRM application of 3D bioprinting is body-on-a-chip technology, which applies cells onto a computer chip to mimic organs.

We can create miniature hearts, lungs, blood vessels, kidneys and brains, put them all together on a chip and actually start to screen drugs over time, Atala said.

The technology can also be used to create tumors on a chip for personalized medicine. Tumor cells harvested from tissue biopsied at the time of a patients cancer diagnosis are applied to a chip and then tested against various chemotherapy drugs so we can best predict what the best treatment is for that patient, before that patient gets the treatment, Atala said.

The cell therapy, 3D bioprinting and body-on-a-chip technologies are just a sampling of WFIRMs work, and we have a lot of things going on, Atala said.

Our mission is to bring these technologies to patients, to improve patients lives through regen med, he said. Our vision is to lead a global transformation from treatments to cures.

Wake Forest Institute for Regenerative Medicine leads new $20M effort (+ video)

Beyond its own research, WFIRM has become a major influencer and resource in regenerative medicine nationally and globally.

It has over 400 research collaborations with scientists across the United States and around the world.

Specialized containers for cell processing.

For most of these collaborations, WFIRM is the one thats providing materials, reagents, cells and know-how, trying to disseminate this information to a global scale, Atala said.

WFIRM also helps prepare the next generation of regenerative medicine scientists through education and training programs for high school students, undergraduates, graduate students and post-doctoral fellows. It also sponsors conferences and workshops, provides content and materials for museum exhibits around the world and publishes textbooks.

The institute has spurred new initiatives and entities in Winston-Salem to advance regenerative medicine nationally and globally. This ecosystem, called the Regenerative Medicine Hub, includes the nonprofit RegenMed Development Organization (ReMDO), a research partner with WFIRM that sponsors several programs to advance the field nationwide, including the Regenerative Manufacturing Innovation Consortium and the Regenerative Medicine Manufacturing Society.

Startup Spotlight: RegeneratOR Test Bed in W-S aims to boost startups focusing on regenerative medicine

Through its RegeneratOR initiative, ReMDO sponsors three programs to support startup and growth companies in regenerative medicine:

These and other resources in the Regenerative Medicine Hub have attracted about30 bioscience companiesto Winston-Salems Innovation Quarter, ranging from local start-ups to multinational corporations.

The latest company to establish a presence at ReMDOs Innovation Accelerator is Houston-basedAxiom Space, developer of the first commercial space station that will supplement and eventually replace the International Space Station.

Axiom will partner with WFIRM and ReMDO to focus on innovations in regenerative medicine manufacturing in space. Research done on the new space station, in low orbit 250 miles above Earth, will be free from the constraints of gravity, providing potential benefits.

Space station builder to lease space in Winston-Salem regenerative medicine accelerator

WFIRM and Winston-Salem have staked an early claim in a promising industry that appears destined for robust growth.

Various consultants reports predict the global market for regenerative medicine will expand at a compound annual growth rate ranging from 9 to 23% during this decade. By 2030 the market will be worth up to $150 billion, according to a report by Verified Market Research of Jersey City, N.J.

Driving that growth are an aging population battling chronic diseases, rising investments in regenerative medicine research, and advances in new technologies and therapies such as those being developed by WFIRM.

Regenerative medicine is an emerging field, Atala said. Were still trying to figure out what is the best next thing that we can do to advance these technologies.

NCBiotech Center

Link:
W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire

Posted in North Carolina Stem Cells | Comments Off on W-S organization working on regenerative therapies for 40 organs, tissues – WRAL TechWire

BioRestorative Therapies Annou – GuruFocus.com

Posted: July 3, 2022 at 1:52 am

MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company or BioRestorative) ( BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestoratives second clinical trial contract executed.

BioRestoratives Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Companys autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

With the signing of our second clinical trial agreement, we are pleased to welcome Dr. Richard Rauck who will be the principal investigator for The Center for Clinical Research, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. Dr. Rauck has extensive clinical experience and brings expertise in the field of cell-based regenerative medicine, which is invaluable for a successful clinical trial.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: [emailprotected]

Here is the original post:
BioRestorative Therapies Annou - GuruFocus.com

Posted in North Carolina Stem Cells | Comments Off on BioRestorative Therapies Annou – GuruFocus.com

How biotechnology will transform the food and agriculture system – Genetic Literacy Project

Posted: July 3, 2022 at 1:49 am

There is no area of human activity more basic to society than a sustainable agricultural, food, and natural resource system. With projections that global population will grow to as much as 10 billion by 2050 (Pew Research Center 2022), there is increasing concern as to how this system should be transformed to feed this population sustainably.

Serious questions need to be addressed; for example: What will constitute a healthy diet? Will natural resources and ecosystems be compromisedor even destroyedin efforts to provide such a diet? Will the food system reduce or increase hunger and poverty? And will the system enhance or decrease equity and access to food for a healthy and productive global population? These and other critical questions challenge all who participate in the food and agriculture system (FAS), and more broadly everyone is involved at some level, from daily consumption to innovative scientific research.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

An article by the CROPPS Research Community emphasizes the need for a deeper understanding of the biology of plants and their responses to a changing climate, among other factors. The vision and work of the Center for Research on Programmable Plant Systems (CROPPS) focus on understanding the deep biology of plants to create an Internet of Living Things. The vision depends on transdisciplinary collaborationbiotechnology and synthetic biology, robotics and automation, sensing and automation, and computingto enable a digital dialogue with plant systems.

This is an excerpt. Read the original post here

Follow this link:
How biotechnology will transform the food and agriculture system - Genetic Literacy Project

Posted in Biotechnology | Comments Off on How biotechnology will transform the food and agriculture system – Genetic Literacy Project

Page 377«..1020..376377378379..390400..»